Valuation: BioRestorative Therapies, Inc.

Market Cap 5.76M 4.97M 4.67M 4.25M 7.99M 550M 8.12M 54.73M 21.4M 276M 21.61M 21.14M 916M P/E 2026 *
-0.46x
P/E 2027 * -0.56x
Enterprise Value 5.76M 4.97M 4.67M 4.25M 7.99M 550M 8.12M 54.73M 21.4M 276M 21.61M 21.14M 916M EV / Sales 2026 *
4.1x
EV / Sales 2027 * 2.49x
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 32 12/07/2026
Investor Relations Contact - -
Corporate Officer/Principal - 21/10/2025
Director TitleAgeSince
Director/Board Member 28 11/06/2026
Director/Board Member 37 11/06/2026
Director/Board Member - 12/07/2026
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%+0.25% - - 5.76M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.21%+1.95%+52.76%+205.60% 29.3B
Weighted average by Cap. -1.09%+0.55%+50.23%+164.99%

Financials

2026 *2027 *
Net sales 1.4M 1.21M 1.14M 1.04M 1.95M 134M 1.98M 13.36M 5.22M 67.28M 5.28M 5.16M 224M 2.31M 2M 1.88M 1.71M 3.21M 221M 3.26M 21.99M 8.6M 111M 8.68M 8.49M 368M
Net income -13.52M -11.68M -10.98M -9.98M -18.77M -1.29B -19.08M -129M -50.28M -648M -50.77M -49.67M -2.15B -15.56M -13.44M -12.63M -11.48M -21.59M -1.49B -21.95M -148M -57.85M -745M -58.41M -57.15M -2.48B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-